The latest developments in the search for better treatments and a cure for macular disease.

Latest news

Drug Vial close up

How are new treatments developed?

Posted: Monday 28 April 2025

Developing new treatments for macular disease is a lengthy process involving many steps. From understanding the causes of a condition, to finding new treatments to test, and finally, going through the stages of clinical trials.

Andrew Lotery using optometrist equipment. Andrew is wearing blue scrubs and glasses and has dark short hair.

Professor Andrew Lotery answers your questions

Posted: Wednesday 5 March 2025

Professor Andrew Lotery discusses the latest approved treatment for wet age-related macular degeneration (AMD), Lytenava and answers your frequently asked questions on treatments and research.

Gene double helix

Gene therapy trial improves sight in blind toddlers

Posted: Tuesday 4 March 2025

Four toddlers born with a severe form of childhood blindness have experienced “life-changing improvements” to their sight after participating in an experimental gene therapy trial. 

Drug Vial close up

Syfovre FAQs and next steps for dry AMD and geographic atrophy treatment

Posted: Thursday 30 January 2025

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) decision to reject the first potential treatment for geographic atrophy (GA), or late-stage age-related macular degeneration (AMD) is undoubtedly a disappointing one for those living with the condition. But, what does the decision mean? We answer your questions.

Scientist with drug vial

First treatment for late-stage dry AMD rejected by UK drug regulator

Posted: Wednesday 22 January 2025

The first potential treatment for geographic atrophy (GA) or late stage dry aged-related macular degeneration has been rejected by the Medicines and Healthcare products Regulatory Agency (MHRA).

Woman on computer in a lab

How artificial intelligence is transforming eye care

Posted: Thursday 9 January 2025

Artificial intelligence (AI) is already part of our daily lives, but how is it changing healthcare? In a recent webinar hosted by Macular Society partner OcuPlan Dr James Neffendorf, an eye specialist at King’s College Hospital and ophthalmic surgeon Dan Calladine, explored how AI is transforming the way eye care is delivered and how it is improving outcomes for patients.

Researcher in laboratory

Explore our research

Beating macular disease through funding medical research and improving the lives of those living with macular disease.

micro biologist with petri dish

Get involved in research

Patients have a very important part to play in medical research. Without them we would not have the treatments we have today and new and improved treatments would not be possible.